Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical Asia Pacific

Firms Should Look To Local CROs For Clinical Trials in Asia

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Asia medical consultant highlights advantages of China and India.

You may also be interested in...



Indian Pharma Focusing On R&D, Licensing – Ranbaxy Exec

Indian firms are flush with cash and looking to move from generic drugs to proprietary compounds, Ranbaxy’s Shyam Bishen tells “The Pink Sheet” DAILY.

Novartis Shanghai R&D Center To Focus On Diseases Prevalent In China

Establishment of the R&D site reflects Novartis’ commitment to the region, according to the drug maker.

Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.

Table

View full table

Topics

Tags:
BioPharmaceutical Asia Pacific
UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By